KRAS and thyroid gland carcinoma: There may be a role for targeted inhibitors of the RAS/MAPK pathway in MLAs, given their underlying KRAS mutations and a clinical study had shown that thyroid carcinomas with KRAS mutations were very sensitive to lenvatinib (30).